Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Investigator And Subject-Blind (Sponsor Unblinded), Placebo-Controlled Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-02545920 After Multiple Oral Dose Administration In Subjects With Stable Schizophrenia

NCT00463372 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00463372
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00463372 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Investigator And Subject-Blind (Sponsor Unblinded), Placebo-Controlled Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-02545920 After Multiple Oral Dose Administration In Subjects With Stable Schizophrenia
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2006
Completion date
May 31, 2007
Enrollment
40
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

schizo-affective disorder, schizophrenia